Gynesonics is a medical device company focused on advancing women's health by developing minimally invasive solutions for the treatment of uterine fibroids and other uterine conditions.

Gynesonics

MVM Partners has been a life science investment fund for more than 25 years and invests broadly across the healthcare sector, including in specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, contract manufacturing, healthcare services, and digital health.

MVM has a global perspective on healthcare and maintains offices in Boston and London. Current MVM portfolio companies are headquartered in the US and Europe, and many have extensive operations in the Middle East and Asia. 

MVM Partners

We are excited today to announce the US FDA approval of XHANCE as the first and only medication indicated for treatment of adults with chronic rhinosinusitis without nasal polyps. Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually. Read more here: https://bit.ly/4aaiN34

We are delighted to welcome Per Langoe to the GT Medical team!

We are extremely proud to feature Long-term and Holistic Outcomes from the COMFORT RCT for PNS.

“Clinicians recognize the value of combining pain relief with functional outcomes to provide a more comprehensive assessment of device effectiveness in treating chronic, intractable pain. In the COMFORT RCT, we are measuring variables that present this broader picture. Results show that the Nalu PNS System is truly unique. For the first time, clinicians have access to advanced technology that enables us to offer effective long-term therapy to a broader range of patients.” -Dr. John Hatheway, first author 

Highlights of the presentation include the following:
	· 98% of subjects using Nalu PNS experienced ≥50% pain relief and/or reported improvement compared with 21% of subjects who did not use Nalu PNS (p<0.001).
	· 93% of subjects using Nalu PNS experienced ≥50% pain relief and/or reduced disability compared with 35% who did not use Nalu PNS (p<0.001).

The right data matters. 

#NaluMed #UnlockBarriers #Treatmorepatients #NANS2024 

https://lnkd.in/g4NZZrX2

We are excited to announce a $30M strategic partnership with MVM Partners a global leader in healthcare venture capital. This partnership is a significant step in our journey, emphasizing not just financial support but a deep alignment with MVM's extensive knowledge and expertise in the healthcare sector. 

🔗Link to full text: https://ow.ly/KpMS50Qu7wf

What does this mean for icotec?
• Strengthening our R&D capabilities.
• Expanding our innovative BlackArmor® product portfolio.
• Addressing new clinical indications.

Since receiving FDA clearance in 2019, our BlackArmor® products have been embraced by top US cancer centers. This adoption, coupled with the recent backing from MVM, sets us on a path to make even greater strides in improving patient outcomes.

We extend our deepest gratitude to healthcare providers worldwide who have been pivotal in this journey. Your expertise, dedication, and compassionate approach have not only advanced the field of spinal health but also underscored our shared vision and commitment to healthcare innovation.

Together, we are driving change and shaping the future of spine care.

#collaboration #icotecmedical #spine #innovation


We are excited to partner with icotec in its mission to revolutionize the spinal implant industry. 

https://lnkd.in/evgHUfGM

We're thrilled to announce a new category 1 CPT code for transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency! 
#FibroidTreatment #SonataProcedure #CPTCode #WomensHealth 

https://bit.ly/3S6ny7y

COM:MVM

Gynesonics

Financials Not Available